Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease

详细信息    查看全文

• 作者：Shaila P. H ; attu ; David W. Garber ; C ; yce E. Monroe ; Thomas van Groen ; Inga Kadish ; Gaurav Nayyar ; Dongfeng Cao ; Mayakonda N. Palgunachari ; Ling Li ; G.M. Anantharamaiah
• 关键词：Apo A-I ; A-I mimetic ; HDL ; Amphipathic peptides ; Amyloid β
• 刊名：Neurobiology of Disease
• 出版年：2009
• 出版时间：June 2009
• 年：2009
• 卷：34
• 期：3
• 页码：525-534
• 全文大小：1570 K

文摘

Recent evidence indicates that inflammation may significantly contribute to the pathogenesis of Alzheimer's disease (AD). Since the apo A-I mimetic peptide D-4F has been shown to inhibit atherosclerotic lesion formation and regress already existing lesions (in the presence of pravastatin) and the peptide also decreases brain arteriole inflammation, we undertook a study to evaluate the efficacy of oral D-4F co-administered with pravastatin on cognitive function and amyloid β (Aβ) burden in the hippocampus of APPSwe-PS1ΔE9 mice. Three groups of male mice were administered D-4F and pravastatin, Scrambled D-4F (ScD-4F, a control peptide) and pravastatin in drinking water, while drinking water alone served as control. The escape latency in the Morris Water Maze test was significantly shorter for the D-4F + statin administered animals compared to the other two groups. While the hippocampal region of the brain was covered with 4.2 ± 0.5 and 3.8 ± 0.6 % of Aβ load in the control and ScD-4F + statin administered groups, in the D-4F + statin administered group Aβ load was only 1.6 ± 0.1 % . Furthermore, there was a significant decrease in the number of activated microglia (p < 0.05 vs the other two groups) and activated astrocytes (p < 0.05 vs control) upon oral D-4F + statin treatment. Inflammatory markers TNFα and IL-1β levels were decreased significantly in the D-4F + statin group compared to the other two groups (for IL-1β p < 0.01 vs the other two groups and for TNF-α p < 0.001 vs control) and the expression of MCP-1 were also less in D-4F + statin administered group compared to the other two groups. These results suggest that the apo A-I mimetic peptide inhibits amyloid β deposition and improves cognitive function via exerting anti-inflammatory properties in the brain.